Fennec Pharmaceuticals Inc. (FRA:RV41)
Germany · Delayed Price · Currency is EUR | Market Cap | 315.65M +51.0% |
| Revenue (ttm) | 51.84M +77.8% |
| Net Income | -2.84M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 22.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18 |
| Open | 8.65 |
| Previous Close | 9.15 |
| Day's Range | 8.65 - 8.95 |
| 52-Week Range | 4.74 - 11.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of oto... [Read more]
Financial Performance
In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$9.74 million, 2134.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Fennec presents results from STS-J01 clinical trial evaluating Pedmark
Fennec (FENC) announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating Pedmark for the reduction of cisplatin-induced ototoxicity i...
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
Fennec Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
PEDMARK, the only FDA-approved therapy for cisplatin-induced hearing loss, is expanding globally with strong IP protection and partnerships. Commercial execution has driven revenue growth and positive EBITDA, with further expansion planned in Europe, Japan, and adult markets.
Fennec Pharmaceuticals Slides: Corporate presentation
Fennec Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
Fennec price target raised to $16 from $13 at Wedbush
Wedbush raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps an Outperform rating on the shares. The firm notes Q2 PEDMARK revenue of $17.2M exceeded…
Fennec price target raised to $18 from $16 at B. Riley
B. Riley raised the firm’s price target on Fennec (FENC) to $18 from $16 and keeps a Buy rating on the shares. The Q2 results de-risk a potential 2H26 revenue…
Fennec Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 78% year-over-year to $17.1 million, with record patient enrollments and infusions driving the seventh consecutive quarter of growth. Expanded commercial and medical teams, innovative awareness campaigns, and strong cash flow position the business for continued momentum.
Fennec Pharmaceuticals Earnings release: Q2 2026
Fennec Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Fennec Pharmaceuticals Quarterly report: Q2 2026
Fennec Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 11, 2026.
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...
Fennec Pharmaceuticals Transcript: AGM 2026
Record sales and financial strength marked 2025, with major growth in PEDMARK and expansion into new markets. All shareholder proposals passed, including board elections and equity plan amendments. Strategic initiatives target broader clinical adoption and global reach.
Fennec price target raised to $16 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps a Buy rating on the shares. Pedmark adoption continues to build across both new…
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
PEDMARK, the only approved agent to prevent cisplatin-induced hearing loss, is expanding from pediatrics into the larger AYA market, driving record revenues and broader adoption. Ongoing real-world studies and global partnerships aim to unlock further growth and long-term exclusivity.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that...
Fennec Pharmaceuticals Slides: Corporate presentation
Fennec Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Fennec Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 73% year-over-year sales growth, driven by commercial expansion and strong demand in key cancer segments. Operational improvements led to record infusions and high conversion rates, while new clinical studies and international launches are set to support further growth.
Fennec Pharmaceuticals Earnings release: Q1 2026
Fennec Pharmaceuticals released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Fennec Pharmaceuticals Quarterly report: Q1 2026
Fennec Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
Fennec reports Q1 EPS 1c, consensus (2c)
Reports Q1 revenue $15.1M, consensus $13.84M. “We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec (FENC), with growing…
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ...
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Proxy statement: Proxy filing
Fennec Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.